CN103599281B - Traditional Chinese medicinal composition for treating obsessive-compulsive disorder and application thereof - Google Patents
Traditional Chinese medicinal composition for treating obsessive-compulsive disorder and application thereof Download PDFInfo
- Publication number
- CN103599281B CN103599281B CN201310569977.0A CN201310569977A CN103599281B CN 103599281 B CN103599281 B CN 103599281B CN 201310569977 A CN201310569977 A CN 201310569977A CN 103599281 B CN103599281 B CN 103599281B
- Authority
- CN
- China
- Prior art keywords
- traditional chinese
- parts
- chinese medicinal
- compulsive
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 20
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 title abstract description 4
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims description 46
- 239000007788 liquid Substances 0.000 claims description 26
- 238000011282 treatment Methods 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 17
- 240000000249 Morus alba Species 0.000 abstract description 2
- 210000000748 cardiovascular system Anatomy 0.000 abstract description 2
- 241000544682 Acorus tatarinowii Species 0.000 abstract 1
- 235000008708 Morus alba Nutrition 0.000 abstract 1
- 241000124033 Salix Species 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 239000012567 medical material Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 229940079593 drug Drugs 0.000 description 15
- 238000004321 preservation Methods 0.000 description 8
- 206010029897 Obsessive thoughts Diseases 0.000 description 6
- 208000030459 obsessive-compulsive personality disease Diseases 0.000 description 5
- 208000007656 osteochondritis dissecans Diseases 0.000 description 5
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 4
- 239000003390 Chinese drug Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 229940069338 potassium sorbate Drugs 0.000 description 4
- 235000010241 potassium sorbate Nutrition 0.000 description 4
- 239000004302 potassium sorbate Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 3
- 206010042674 Swelling Diseases 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 208000005946 Xerostomia Diseases 0.000 description 2
- 229960004606 clomipramine Drugs 0.000 description 2
- 231100000895 deafness Toxicity 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000016354 hearing loss disease Diseases 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000006794 tachycardia Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 244000001632 Acorus gramineus Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 240000005528 Arctium lappa Species 0.000 description 1
- 235000003130 Arctium lappa Nutrition 0.000 description 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 208000037319 Hepatitis infectious Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- DINOPBPYOCMGGD-VEDJBHDQSA-N Man(a1-2)Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-6)]Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc Chemical compound O[C@@H]1[C@@H](NC(=O)C)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO[C@@H]3[C@H]([C@@H](O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)O3)O)O2)O)[C@@H](CO)O1 DINOPBPYOCMGGD-VEDJBHDQSA-N 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 244000020191 Salix babylonica Species 0.000 description 1
- 235000002493 Salix babylonica Nutrition 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 229960004372 aripiprazole Drugs 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 201000002327 urinary tract obstruction Diseases 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicinal composition for treating obsessive-compulsive disorder and application thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicinal composition is prepared from the following traditional Chinese medicinal raw materials in parts by weight: 50-80 parts of willow twig, 15-30 parts of fructus arctii, 15-30 parts of acorus tatarinowii and 15-30 parts of mulberry leaf. The traditional Chinese medicinal composition has a remarkable curative effect in treating obsessive-compulsive disorder, does not have remarkable side effect or adverse influence on a cardiovascular system, and has popularization value.
Description
Technical field
The invention belongs to technical field of Chinese medicines, be specifically related to one and treat compulsive Chinese medicine composition and application thereof.
Background technology
Obsession (Obsessive compulsive disorder, OCD) forces with uncontrollable the neurosis that thinking and compulsive act are feature.Its symptom obviously affects the activity of daily living of patient, and course of disease delay, often cause serious functional lesion.It is generally acknowledged that just having a people in every 50 people must cross obsession, just there are more than 100 ten thousand patients with OCDs in such as Britain, teenager prevalence is very high, it is generally acknowledged that adolescence suffers from obsession all can rehabilitation before growing up, external report sickness rate is 2%, also psychologist is had to think sickness rate at least 10%, without difference on Sex distribution.Along with the development of society, modern, as geek's residence female, if people is lonely for a long time be also easy to the seed that occurs forcing psychology in specific minor matter in the face of computer.Prevention obsession needs sufficient sleep, suitable motion, frequent joined body doings.
Compulsive morbidity is unbalance relevant with various neurotransmitters in brain, and main manifestations is the disorder of 5-hydroxy tryptamine systemic-function.The anti-medicine that forces of current use is all antidepressants, and its feature is just to regulate the function of the neurotransmitter such as 5-hydroxy tryptamine in brain, thus reaches the effect improving obsessive symptoms.Use and many be mainly selective serotonin reuptake inhibitor (SSRIs), comprise fluvoxamine, paroxetine, Sertraline, fluoxetine, citalopram etc., and tricyclic antidepressant clomipramine, also use propranolol and benzodiazepine to assist reduction of patient anxiety if desired clinically, improve insomnia.As synergist, curative effect is improved for the normal use in conjunction risperidone of refractory obsessive-compulsive, Quetiapine, olanzapine, Aripiprazole etc.
Obsession treatment needs Long-term taking medicine, and Western medicine has larger side effect, as xerostomia, feel sick, constipation, tachycardia, dizziness, tremble, dysuria etc., and easily cause ECG change, be unfavorable for the interdependence improving patient medication.Therefore, develop a kind of good effect, instant effect, the medicine that toxic and side effects is little seems particularly important.
Summary of the invention
An object of the present invention is, by prescription again after studying Chinese medicine pharmacology, to provide a kind of good effect, instant effect, the compulsive Chinese medicine composition of the treatment that toxic and side effects is little.
The object of the present invention is achieved like this:
One treats compulsive Chinese medicine composition, is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Ramulus Salicis Babylonicae 50-80 part, Fructus Arctii 15-30 part, Rhizoma Acori Graminei 15-30 part, Folium Mori 15-30 part.
Preferably, the compulsive Chinese medicine composition for the treatment of as mentioned above, it is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Ramulus Salicis Babylonicae 60-70 part, Fructus Arctii 20-25 part, Rhizoma Acori Graminei 20-25 part, Folium Mori 20-25 part.
In the present invention's most preferred embodiment, the compulsive Chinese medicine composition for the treatment of as mentioned above, it is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Ramulus Salicis Babylonicae 66 parts, Fructus Arctii 20 parts, Rhizoma Acori Graminei 20 parts, 20 parts, Folium Mori.
Further preferably, the compulsive Chinese medicine composition for the treatment of as above, it is oral formulations, comprises tablet, capsule, granule and oral liquid.
Found by lot of experiments research, the pharmaceutical composition be made up of above-mentioned traditional Chinese medicinal material raw materials has significant curative effect in treatment patients with OCD.Therefore, second object of the present invention is to provide a kind of new medical use, the application of namely above-mentioned Chinese medicine composition in the compulsive medicine of preparation treatment.
According to Chinese medicine Historical Data Data About, above-mentioned traditional Chinese medicinal material raw materials has following pharmacologically active and function cures mainly:
Ramulus Salicis Babylonicae: dispel the wind, diuresis, pain relieving, detumescence.Dispelling the wind and dampness pathogens arthralgia pain, gonorrhea, nebulousurine, urinary obstruction, infectious hepatitis, swelling due to wind, furuncle, erysipelas, dental caries, swelling of the gum.Select the dry branch of Salicaceous Plants Salix babylonica L..
Rhizoma Acori Graminei: removing dampness is whetted the appetite, eliminating phlegm of having one's ideas straightened out, refreshment Fructus Alpiniae Oxyphyllae.Not hungry for gastral cavity painful abdominal mass, a mouthful dysentery of keeping silent, coma epilepsy, forgetful deafness.Regulate the flow of vital energy, invigorate blood circulation, loose wind, dries.Control epilepsy, syncope due to accumulation of phlegm, calentura coma, forgetful, deafness with qi stagnation, ambition is unhappy, stomachache, stomachache, anemofrigid-damp arthralgia, swollen ulcer drug, traumatic injury.Derive from the rhizome of acorus gramineus araceae plant.
Fructus Arctii: the effect with dispelling wind and heat pathogens, lung qi dispersing rash, sore-throat relieving eliminating stagnation, removing toxic substances and promoting subsidence of swelling, cure mainly cough due to pathogenic wind-heat, laryngopharynx swelling and pain, macule not thoroughly, rubella pruritus, sore swollen toxin.Be selected from the dry mature fruit of feverfew Fructus Arctii Arctium lappa L..
Folium Mori: there is dispelling wind and heat pathogens, clearing away lung-heat and moistening for dryness, suppressing liver-YANG, liver heat removing and eyesight improving, effect of cooling blood for hemostasis.Select the dried leaves of Moraceae Moraceae plant Mulberry Morus alba L..
Above-mentioned each Chinese crude drug is prepared into the preparation method of compound preparation of the present invention, comprises the steps:
(1) take above-mentioned each traditional Chinese medicinal material raw materials, clean roguing, dry, be ground into granule;
(2) graininess medical material is added water cover powder 2cm again, soak 1-1.2h, pull medical material out and put during multi-functional extractions is filled with and decoct with water secondary, first time totalling medical material volume the water of 8-10 times amount, decoct 2h, get decocting liquid, filter, second time adds up the water of the 6-8 times amount of medical material volume, decoct 1h, get twice decocting liquid to merge, filter, when being concentrated into 90 DEG C, relative density is the concentrated solution of 1.10;
(3) concentrated solution is set to 0-5 DEG C of deepfreeze 24h, cold preservation liquid is added the filter aid kieselguhr of appropriate 0.3%, filter, filtrate reconcentration contains 2.5-3.0g crude drug amount to every milliliter, then adds the potassium sorbate of 0.2%, stirs, set to 0-5 DEG C of deepfreeze 24h, cold preservation liquid is filtered, obtains oral liquid.
Test through embodiment 4 and prove, compared with prior art, the traditional Chinese medicine composition for treating that the present invention relates to is compulsive evident in efficacy, and non-evident effect, cardiovascular system is had no adverse effects, is worth at clinical expansion.
Detailed description of the invention
Be below specific embodiments of the invention, technical scheme of the present invention is done to describing further, but protection scope of the present invention be not limited to these embodiments.Every do not deviate from the present invention's design change or equivalent substituting include within protection scope of the present invention.
the preparation of embodiment 1 Chinese medicine oral liquid
Crude drug prescription: Ramulus Salicis Babylonicae 6.6 kilograms, Fructus Arctii 2 kilograms, Rhizoma Acori Graminei 2 kilograms, 2 kilograms, Folium Mori.
Preparation method:
(1) take above-mentioned Chinese crude drug, clean roguing, dry, pulverize;
(2) graininess medical material is added water cover powder 2cm again, soak 1-1.2h, pull medical material out and put during multi-functional extractions is filled with and decoct with water secondary, first time totalling medical material volume the water of 8 times amount, decoct 2h, get decocting liquid, filter, second time adds up the water of 8 times amount of medical material volume, decoct 1h, get twice decocting liquid to merge, filter, when being concentrated into 90 DEG C, relative density is the concentrated solution of 1.10;
(3) concentrated solution is set to 0-5 DEG C of deepfreeze 24h, cold preservation liquid is added the filter aid kieselguhr of appropriate 0.3%, filter, filtrate reconcentration containing 2.5g crude drug amount, then adds the potassium sorbate of appropriate 0.2% to every milliliter, stirs, put 5 DEG C of deepfreeze 24h, cold preservation liquid is filtered, obtains oral liquid.
the preparation of embodiment 2 Chinese medicine oral liquid
Crude drug prescription: Ramulus Salicis Babylonicae 6 kilograms, Fructus Arctii 1.8 kilograms, Rhizoma Acori Graminei 3.0 kilograms, 2.5 kilograms, Folium Mori.
Preparation method:
(1) take above-mentioned Chinese crude drug, clean roguing, dry, pulverize;
(2) graininess medical material is added water cover powder 2cm again, soak 1-1.2h, pull medical material out and put during multi-functional extractions is filled with and decoct with water secondary, first time totalling medical material volume the water of 10 times amount, decoct 2h, get decocting liquid, filter, second time adds up the water of 8 times amount of medical material volume, decoct 1h, get twice decocting liquid to merge, filter, when being concentrated into 90 DEG C, relative density is the concentrated solution of 1.10;
(3) concentrated solution is set to 0-5 DEG C of deepfreeze 24h, cold preservation liquid is added the filter aid kieselguhr of appropriate 0.3%, filter, filtrate reconcentration containing 2.5g crude drug amount, then adds the potassium sorbate of appropriate 0.2% to every milliliter, stirs, set to 0 a DEG C deepfreeze 24h, cold preservation liquid is filtered, obtains oral liquid.
the preparation of embodiment 3 Chinese medicine oral liquid
Crude drug prescription: Ramulus Salicis Babylonicae 7.2 kilograms, Fructus Arctii 2.6 kilograms, Rhizoma Acori Graminei 2.2 kilograms, 1.8 kilograms, Folium Mori.
Preparation method:
(1) take above-mentioned Chinese crude drug, clean roguing, dry, pulverize;
(2) graininess medical material is added water cover powder 2cm again, soak 1-1.2h, pull medical material out and put during multi-functional extractions is filled with and decoct with water secondary, first time totalling medical material volume the water of 8 times amount, decoct 2h, get decocting liquid, filter, second time adds up the water of 6 times amount of medical material volume, decoct 1h, get twice decocting liquid to merge, filter, when being concentrated into 90 DEG C, relative density is the concentrated solution of 1.10;
(3) concentrated solution is set to 0-5 DEG C of deepfreeze 24h, cold preservation liquid is added the filter aid kieselguhr of appropriate 0.3%, filter, filtrate reconcentration containing 3.0g crude drug amount, then adds the potassium sorbate of appropriate 0.2% to every milliliter, stirs, set to 0 a DEG C deepfreeze 24h, cold preservation liquid is filtered, obtains oral liquid.
embodiment 4 Chinese medicine composition of the present invention is to the effectiveness study of patients with OCD
32 routine patients with OCDs, meet the compulsive diagnostic criteria of CCMD-2-R: obsession scale (Y-BOCS) is marked > 16 points, and the age is in 18-56 year; Get rid of brain organic disease and severe physical disease.All patients are divided into following two groups at random: Chinese drug-treated group men and women each 8 example, the mean age (35.7 ± 13.1) year; Western medicine group man 9 example, female 7 example, the mean age (36.4 ± 14.2) year.The sex of two groups, age and coincident with severity degree of condition are through statistical procedures there was no significant difference.Chinese drug-treated group patient takes Chinese medicine oral liquid prepared by the embodiment of the present invention 1, and early, evening respectively takes 40mL.The oral Clomipramine treatment of Western medicine group, initial dose 25mg/d, increases to 100-250mg/d gradually according to the state of an illness.Two groups of equal medications of patient treat 2 months.
Two groups of patients all evaluate once with Y-BOCS for before treatment and after treatment every 2 weeks, with its deduction rate evaluation clinical efficacy (>=50% is recovery from illness, and >=35% is effective, and >=20% is that effectively < 20% is invalid).In time entering to organize and treatment at the end of have a blood test respectively, routine urinalysis, liver function, electrocardiogram etc.
By above efficacy assessment standard, medication terminates rear Chinese drug-treated group recovery from illness 6 example, effective 4 examples, effective 4 examples, invalid 2 examples; Western medicine group recovery from illness 4 example, effective 3 examples, effective 5 examples, invalid 4 examples.Two groups of obvious effective rates are respectively 62.5% and 43.8%, and effective percentage is respectively 87.5% and 75%, through statistical procedures there was no significant difference.
Front and back Y-BOCS scoring situation treated by table 1
Compare with before treatment,
★ p< 0.05,
★ ★ p< 0.01.
Shown by the result of table 1, after two groups of Y-BOCS scoring treatments, all have significant difference compared with before treatment.Difference of comparing between two groups after treatment is not obvious.In addition, Chinese drug-treated group patient is without obvious side reaction after treatment, and electrocardiogram is also without change; The side reaction of Western medicine group is more, as xerostomia, feel sick, constipation, tachycardia, dizziness, tremble, dysuria, ECG change etc.In side effect, two groups are compared and have significant difference.
Claims (3)
1. treat a compulsive Chinese medicine composition, it is characterized in that: described Chinese medicine composition is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Ramulus Salicis Babylonicae 66 parts, Fructus Arctii 20 parts, Rhizoma Acori Graminei 20 parts, 20 parts, Folium Mori.
2. the compulsive Chinese medicine composition for the treatment of according to claim 1, is characterized in that: described Chinese medicine composition is tablet, capsule, granule and oral liquid.
3. the application of the compulsive Chinese medicine composition for the treatment of according to claim 1 in the compulsive medicine of preparation treatment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310569977.0A CN103599281B (en) | 2013-11-16 | 2013-11-16 | Traditional Chinese medicinal composition for treating obsessive-compulsive disorder and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310569977.0A CN103599281B (en) | 2013-11-16 | 2013-11-16 | Traditional Chinese medicinal composition for treating obsessive-compulsive disorder and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103599281A CN103599281A (en) | 2014-02-26 |
| CN103599281B true CN103599281B (en) | 2015-07-15 |
Family
ID=50117587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310569977.0A Active CN103599281B (en) | 2013-11-16 | 2013-11-16 | Traditional Chinese medicinal composition for treating obsessive-compulsive disorder and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103599281B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104188447B (en) * | 2014-08-22 | 2016-05-11 | 何贞芳 | One is exclusively used in compulsive therapy pillow |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101934057A (en) * | 2010-10-12 | 2011-01-05 | 姚春雨 | Traditional Chinese medicine for treating schizophrenia |
| CN103285251A (en) * | 2012-02-29 | 2013-09-11 | 黑龙江康元神经专科医院有限责任公司 | Traditional Chinese medicine preparation for treating obsessive-compulsive disorder |
-
2013
- 2013-11-16 CN CN201310569977.0A patent/CN103599281B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103599281A (en) | 2014-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103599281B (en) | Traditional Chinese medicinal composition for treating obsessive-compulsive disorder and application thereof | |
| CN101194982B (en) | Anti-depression traditional Chinese medicine composition and preparation method thereof | |
| CN102397341A (en) | Traditional Chinese medicine for treating oxyhepatitis | |
| CN107412661A (en) | A kind of Chinese medicine composition for treating impotence, premature ejaculation and preparation method thereof | |
| CN103705632A (en) | Application of mammary aggregation dispersing tablets in preparation of medicines for treating penis hardening disease | |
| CN103611027B (en) | The pharmaceutical composition of a kind of clinical prevention, nursing and treatment trichomonal vaginitis | |
| CN102357215A (en) | Ointment for treating right hypochondriac distention and pain caused by acute and chronic cholecystitis | |
| CN103386101B (en) | Traditional Chinese medicine preparation for nonspecific cystitis treatment and preparation method thereof | |
| CN101829188B (en) | Medicament for treating urinary infection and lithiasis | |
| CN101623457B (en) | Traditional Chinese medicine for treating chronic prostatitis | |
| CN101336990B (en) | Medicine for treating cholecystitis | |
| CN1286515C (en) | Medicinal composition for treating cyst | |
| CN104689020A (en) | Detoxication pill for bladder cancer | |
| CN1262292C (en) | Medicie composition, preparing method and use for preparing gynaecopathia medicine | |
| CN101618118B (en) | Application of Chinese medicinal composition in preparing medicament for treating cystitis | |
| CN1899428B (en) | Chinese medicine preparation for treating pain and its preparing method | |
| CN1981835B (en) | Chinese-medicinal contraceptive liquid and its production | |
| CN100534482C (en) | Soft capsule for treating vascular headaehe | |
| CN105079717A (en) | Pharmaceutical preparation for treating depression | |
| CN100531767C (en) | Capsules for treating prostatauxe | |
| CN100360163C (en) | Externally-applied Chinese medicine for treating acute and chronic pharyngolaryn gitis and its therapeutic belt thereof | |
| CN102319390A (en) | The medicine of treatment chronic cholecystitis | |
| CN104689121B (en) | A kind of preparation method for the treatment of the medicament of pruritus vulvae | |
| CN104436017A (en) | Traditional Chinese medicine composition containing caulis akebiae for treating gout | |
| CN114869978A (en) | A Chinese medicinal composition for treating gynecological inflammation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Ma Zhiwen Inventor after: Liu Haozhi Inventor before: Liu Xuejian |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LIU XUEJIAN TO: MA ZHIWEN LIU HAOZHI |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170505 Address after: 226200 Jiangsu province Nantong Jiulong Zhen Yuan Dong Cun highstar Chemical Co. Ltd. in Patentee after: Qidong Su Xing carbon dioxide Co., Ltd. Address before: Jimo City, Shandong province 266200 Jhengtong street Qingdao City No. 20 Patentee before: Li Weili |